PLUS1
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 38.24 ▼ -0.08 (-0.21%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | PFE | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.08% | 38.32 | 38.38 | 38.10 | 38.10 | 38.29 | 18:00:04 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 53,644 | 14,971,279 | $ 38.26 | $ 572,784,696 | 20,733,721 | 33.97 - 44.90 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:55:38 | bunched | 45,876 | $ 38.32 | USD |
Pfizer Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 212.07B | 5.53B | $ 11.15B | 1.88 | 13.20 | 5.52B |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 51.66M | $ 1.36 | 3.55% | 11/07/19 | 23.00 | 0.30% |
Pfizer News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/09/2019 | 19:16 | Dow Jones News | Big Drugmakers Push Deeper Into Cancer Treatment -- 4th.. |
| 12/09/2019 | 16:37 | Dow Jones News | Big Drugmakers Push Deeper Into Cancer Treatment -- 3rd.. |
| 12/09/2019 | 14:33 | Dow Jones News | Big Drugmakers Push Deeper Into Cancer Treatment -- 2nd.. |
| 12/03/2019 | 15:40 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 12/03/2019 | 10:45 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 12/03/2019 | 10:45 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 12/03/2019 | 10:45 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PFE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 38.77 | 38.89 | 37.7721 | 38.17 | 14,582,998 | -0.45 | -1.16% |
| 1 Month | 36.88 | 38.89 | 36.30 | 37.74 | 19,789,958 | 1.44 | 3.9% |
| 3 Months | 36.77 | 38.94 | 34.60 | 37.01 | 18,666,242 | 1.55 | 4.22% |
| 6 Months | 43.24 | 44.5613 | 33.97 | 38.43 | 21,993,803 | -4.92 | -11.38% |
| 1 Year | 44.14 | 44.90 | 33.97 | 40.22 | 22,956,447 | -5.82 | -13.19% |
| 3 Years | 31.11 | 46.47 | 30.90 | 37.74 | 20,086,477 | 7.21 | 23.18% |
| 5 Years | 31.55 | 46.47 | 28.25 | 35.43 | 22,597,833 | 6.77 | 21.46% |
Pfizer Description
| Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor, representing over a fifth of total company sales. |
